FDA Drug Safety Communication: Patients who do not have their gallbladders stop taking Viberzi IMMEDIATELY

Based on a new warning from the U.S. Food and Drug Administration, Southeast Gastro physicians are recommending patients with their gallbladders stop taking Viberzi IMMEDIATELY.

The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns.

To Read the entire FDA Warning, Click Here.